Gastric Inhibitory Polypeptide Receptor - Drugs In Development, 2021
Summary Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor - Drugs In Development, 2021, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 8, 8, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System, Musculoskeletal Disorders, Cardiovascular and Respiratory which include indications Obesity, Type 2 Diabetes, Diabetes, Non-Alcoholic Steatohepatitis (NASH), Alzheimer’s Disease, Non Alcoholic Fatty Liver Disease (NAFLD), Parkinson’s Disease, Cardiovascular Risk Factors, Circadian Rhythm Sleep Disorders, Diastolic Heart Failure, Fibrosis, Idiopathic Pulmonary Fibrosis, Osteoporosis, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, Type 1 Diabetes (Juvenile Diabetes) and Unspecified Metabolic Disorders.
Furthermore, this report also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects - The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics
Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Sep 2021
Major players in the protein expression market are Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., New England Biolabs and Promega Corporation. The global protein expression market is expected to grow from $2.01 billion in 2020 to $2.13 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG, and Novo Nordisk A/S. The global biosimilar therapeutic peptides market is expected to grow from $0.76 billion in 2020 to $0.87...
The global chromatography resins market grew at a CAGR of around 7% during 2015-2020. Chromatography resins provide support to polysaccharide beads that are packed into a column. They are available with different purification efficiency, flow resistance and binding capacity. Some of the commonly utilized chromatography...
The global chemoinformatics market exhibited strong growth during 2015-2020. Looking forward, the analyst expects the market to grow at a CAGR of 13% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic...
120 pages •
By Infiniti Research Limited
• Jun 2021
Global Capillary Electrophoresis Market 2021-2025 The analyst has been monitoring the capillary electrophoresis market and it is poised to grow by $ 248.09 mn during 2021-2025, progressing at a CAGR of 5.85% during the forecast period. Our report on the capillary electrophoresis market provides a holistic analysis, market...
The global wearable injectors market is projected to reach USD 11.5billion by 2026 from USD 7.2billion in 2021, at a CAGR of 9.9% during the forecast period. Growth in this market is mainly driven by factors such as the shift of healthcare delivery toward homecare due to COVID-19, advantages of wearable injectors in the administration of various...
The pen needles market is expected to reach USD 2.2 Billion by 2026 from an estimated USD 1.3 Billion in 2021, at a CAGR of 11.2%. Growth in the market is largely driven by the growing prevalence of chronic diseases and the favorable reimbursement scenario in selected countries. On the other hand, the preference for alternative modes of drug...
The oxidative stress assay market is projected to reach USD 1,326 million by 2025 from USD 836 million in 2020, at a CAGR of 9.7%. Growth in the oxidative stress assay market can be attributed to growth in the biopharmaceutical industry and increasing public-sector funding for academic research. Other important factors aiding the growth of...
17 pages •
By Euromonitor International
• Mar 2021
Natural increase will be the only driver of population growth in Kenya in 2020-2040. Ageing will accelerate over this time, but Kenya will remain young in a global context. An expanding workforce over this timeframe will create the potential of an economic dividend, but only if job creation can keep up. Despite surging urbanisation, urbanites...
Net Migration Rate
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.